| Year |
Citation |
Score |
| 2023 |
DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg HJ, Zhang L, Gore SD, Al Baghdadi T, Maciejewski JP, Liu JJ, Padron E, Komrokji RS, Saber W, et al. Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. Blood Advances. PMID 36947201 DOI: 10.1182/bloodadvances.2022008578 |
0.312 |
|
| 2022 |
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, Devlin SM, Creignou M, Pinel P, Monnier L, Gundem G, Medina-Martinez JS, Domenico D, Jädersten M, Germing U, ... ... Bejar R, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. Nejm Evidence. 1: EVIDoa2200008. PMID 38319256 DOI: 10.1056/EVIDoa2200008 |
0.301 |
|
| 2022 |
Huang YJ, Chen JY, Yan M, Davis AG, Miyauchi S, Chen L, Hao Y, Katz S, Bejar R, Abdel-Wahab O, Fu XD, Zhang DE. RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS. Blood Advances. PMID 36206200 DOI: 10.1182/bloodadvances.2022007804 |
0.326 |
|
| 2020 |
Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, Levine MF, Arango JE, Zhou Y, Solé F, Cargo CA, ... ... Bejar R, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine. PMID 32747829 DOI: 10.1038/S41591-020-1008-Z |
0.48 |
|
| 2020 |
Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, et al. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood. PMID 32347921 DOI: 10.1182/Blood.2020004850 |
0.471 |
|
| 2020 |
Park SJ, Bejar R. Clonal Hematopoiesis in Cancer. Experimental Hematology. PMID 32044376 DOI: 10.1016/J.Exphem.2020.02.001 |
0.371 |
|
| 2020 |
Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma. 1-10. PMID 32026740 DOI: 10.1080/10428194.2020.1723013 |
0.406 |
|
| 2019 |
Bejar R. Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1444-1447. PMID 31766023 DOI: 10.6004/Jnccn.2019.5032 |
0.43 |
|
| 2019 |
Reilly B, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R. DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Advances. 3: 2845-2858. PMID 31582393 DOI: 10.1182/Bloodadvances.2019000192 |
0.399 |
|
| 2019 |
Stoner SA, Yan M, Liu KTH, Arimoto KI, Shima T, Wang HY, Johnson DT, Bejar R, Jamieson C, Guan KL, Zhang DE. Hippo Kinase Loss Contributes to Del(20q) Hematologic Malignancies through Chronic Innate Immune Activation. Blood. PMID 31434702 DOI: 10.1182/Blood.2019000170 |
0.347 |
|
| 2019 |
Bell JA, Galaznik A, Pompilus F, Strzok S, Bejar R, Scipione F, Fram RJ, Faller DV, Cano S, Marquis P. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes. 3: 35. PMID 31218454 DOI: 10.1186/S41687-019-0123-4 |
0.388 |
|
| 2019 |
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, et al. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia & Lymphoma. 1-11. PMID 31111762 DOI: 10.1080/10428194.2019.1616186 |
0.38 |
|
| 2019 |
Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. PMID 30846499 DOI: 10.3324/Haematol.2018.214155 |
0.426 |
|
| 2019 |
Tanaka TN, Bejar R. MDS overlap disorders and diagnostic boundaries. Blood. PMID 30670443 DOI: 10.1182/Blood-2018-10-844670 |
0.385 |
|
| 2019 |
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, ... ... Bejar R, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. PMID 30635634 DOI: 10.1038/S41375-018-0351-2 |
0.471 |
|
| 2019 |
Bernard E, Nannya Y, Yoshizato T, Hasserjian RP, Saiki R, Shiozawa Y, Devlin SM, Tuechler H, Sarian A, Malcovati L, Sole F, Haase D, Creignou M, Levine M, Germing U, ... ... Bejar R, et al. TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes Blood. 134: 675-675. DOI: 10.1182/Blood-2019-129392 |
0.364 |
|
| 2019 |
Bell JA, Pompilus FA, Rams A, Zhu Y, Ciesluk A, Bejar R, Fram RJ, Faller DV, Marquis P. Patient-Centered Evaluation of Clinical Benefit in Acute Myeloid Leukemia: Importance of Early Engagement with Patients Blood. 134: 5898-5898. DOI: 10.1182/Blood-2019-128517 |
0.354 |
|
| 2019 |
Goll JB, Lindsley RC, Hooper WF, Bejar R, Walker J, Fulton R, Abel GA, Al Baghdadi T, Deeg HJ, DeZern AE, Ebert B, Epling-Burnette P, Foran JM, Gorak EJ, Gore SD, et al. Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study Blood. 134: 4271-4271. DOI: 10.1182/Blood-2019-126978 |
0.449 |
|
| 2018 |
Park SJ, Bejar R. Clonal Hematopoiesis in Aging. Current Stem Cell Reports. 4: 209-219. PMID 30854305 DOI: 10.1007/S40778-018-0133-9 |
0.333 |
|
| 2018 |
Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers. 11. PMID 30583461 DOI: 10.3390/Cancers11010011 |
0.412 |
|
| 2018 |
Bejar R. What biologic factors predict for transformation to AML? Best Practice & Research. Clinical Haematology. 31: 341-345. PMID 30466744 DOI: 10.1016/J.Beha.2018.10.002 |
0.434 |
|
| 2018 |
Ozturk K, Dow M, Carlin DE, Bejar R, Carter H. The emerging potential for network analysis to inform precision cancer medicine. Journal of Molecular Biology. PMID 29908887 DOI: 10.1016/J.Jmb.2018.06.016 |
0.33 |
|
| 2018 |
Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germline Tissues for Optimal Somatic Variant Detection in Myelodysplastic Syndromes (MDS). Blood. PMID 29661788 DOI: 10.1182/Blood-2018-01-827881 |
0.324 |
|
| 2018 |
Jonas BA, Curtin PT, Schiller GJ, Jeyakumar D, Wieduwilt MJ, Abedi M, Bejar R, Chow H, Oesterich LG, Logan AC. A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503 Blood. 132: 3088-3088. DOI: 10.1182/Blood-2018-99-119237 |
0.305 |
|
| 2018 |
Bell JA, Pompilus FA, Christian A, Mazerolle F, Scipione F, Bejar R, Galaznik A, Fram RJ, Faller DV, Cano S, Regnault A. Assessing Patient-Reported Outcomes in People with Myelodysplastic Syndromes: Can a Customized Selection of Items from the EORTC Library Enhance the EORTC QLQ-C30? Blood. 132: 4856-4856. DOI: 10.1182/Blood-2018-99-116977 |
0.301 |
|
| 2018 |
Reilly BM, Tanaka TN, Diep D, Yeerna H, Tamayo P, Zhang K, Bejar R. DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS Blood. 132: 106-106. DOI: 10.1182/Blood-2018-99-111535 |
0.318 |
|
| 2017 |
Sallman DA, Tanaka TN, List A, Bejar R. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. 17: 613-620. PMID 29025689 DOI: 10.1016/J.Clml.2017.09.018 |
0.424 |
|
| 2017 |
Nazha A, Bejar R. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS. Current Hematologic Malignancy Reports. PMID 28844082 DOI: 10.1007/S11899-017-0407-9 |
0.406 |
|
| 2017 |
Bejar R. CHIP, ICUS, CCUS and other four-letter words. Leukemia. 31: 1869-1871. PMID 28592887 DOI: 10.1038/Leu.2017.181 |
0.449 |
|
| 2017 |
Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF. New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting. 37: 480-494. PMID 28561687 DOI: 10.14694/EDBK_175397 |
0.375 |
|
| 2017 |
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Research. 77: 1510-1541. PMID 28373404 DOI: 10.1158/0008-5472.Can-16-2346 |
0.342 |
|
| 2017 |
Bejar R, Greenberg PL. The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related Disorders. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 131-135. PMID 28040723 DOI: 10.6004/Jnccn.2017.0010 |
0.386 |
|
| 2017 |
Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 60-87. PMID 28040720 DOI: 10.6004/Jnccn.2017.0007 |
0.353 |
|
| 2017 |
Galanina N, Goodman A, Tran L, Bejar R, Choi MY, Kurzrock R. Next generation sequencing to reveal potentially actionable alterations in the majority of patients with hematologic malignancies. Journal of Clinical Oncology. 35: e23133-e23133. DOI: 10.1200/Jco.2017.35.15_Suppl.E23133 |
0.347 |
|
| 2017 |
Bell JA, Galaznik A, Pompilus FA, Strzok S, Bejar R, Fram RJ, Faller DV, Marquis P. Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank Blood. 130: 3457-3457. DOI: 10.1182/Blood.V130.Suppl_1.3457.3457 |
0.351 |
|
| 2017 |
Jonas BA, Logan AC, Jeyakumar D, Abedi M, Bejar R, Wieduwilt MJ, Oesterich LG, Curtin PT. A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503 Blood. 130: 2973-2973. DOI: 10.1182/Blood.V130.Suppl_1.2973.2973 |
0.336 |
|
| 2016 |
Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. Current Opinion in Hematology. PMID 27875374 DOI: 10.1097/Moh.0000000000000313 |
0.366 |
|
| 2016 |
Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia Research. 52: 1-7. PMID 27855285 DOI: 10.1016/J.Leukres.2016.11.004 |
0.324 |
|
| 2016 |
Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM. Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America. PMID 27638202 DOI: 10.1073/Pnas.1608077113 |
0.336 |
|
| 2016 |
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, et al. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. Bmc Cancer. 16: 652. PMID 27538433 DOI: 10.1186/S12885-016-2710-6 |
0.412 |
|
| 2016 |
Qiu J, Zhou B, Thol F, Zhou Y, Chen L, Shao C, DeBoever C, Hou J, Li H, Chaturvedi A, Ganser A, Bejar R, Zhang DE, Fu XD, Heuser M. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. Rna (New York, N.Y.). PMID 27492256 DOI: 10.1261/Rna.056101.116 |
0.453 |
|
| 2016 |
Bejar R. Splicing Factor Mutations in Cancer. Advances in Experimental Medicine and Biology. 907: 215-28. PMID 27256388 DOI: 10.1007/978-3-319-29073-7_9 |
0.427 |
|
| 2016 |
George TI, Erba HP, Steensma DP, Pollyea DA, Abedi M, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki D, Roboz GJ, Savona MR, Scott BL, et al. Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry Blood. 128: 3548-3548. DOI: 10.1182/Blood.V128.22.3548.3548 |
0.31 |
|
| 2016 |
Nazha A, Sekeres MA, Bejar R, Barnard J, Al-Issa K, Przychodzen BP, Kalaycio M, Clemente MJ, Hirsch CM, Ebert BL, Maciejewski JP. Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes Blood. 128: 3193-3193. DOI: 10.1182/Blood.V128.22.3193.3193 |
0.328 |
|
| 2016 |
Tanaka TN, Reilly B, Diep D, Zhang K, Bejar R. Methylation Profiling Among Patients with TET2 Mutations in Myelodysplastic Syndromes Is Associated with Overall Survival Blood. 128: 3158-3158. DOI: 10.1182/Blood.V128.22.3158.3158 |
0.422 |
|
| 2016 |
Drusbosky L, Singh NK, Tiwari P, Vali S, Abbasi T, Sarkaria S, Lorant A, Burns S, Bejar R, Cogle CR. A Genomic Rule Predicting HMA Treatment Response in MDS Identified By Protein Network Mapping and Validated By Clinical Trial Simulation Blood. 128: 3151-3151. DOI: 10.1182/Blood.V128.22.3151.3151 |
0.4 |
|
| 2015 |
Song C, Castellanos-Rizaldos E, Bejar R, Ebert BL, Makrigiorgos GM. DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples. Clinical Chemistry. PMID 26432802 DOI: 10.1373/Clinchem.2015.245357 |
0.397 |
|
| 2015 |
Kwok B, Hall JM, Witte JS, Xu Y, Reddy P, Lin K, Flamholz R, Dabbas B, Yung A, Al Hafidh J, Balmert E, Vaupel C, El Hader C, McGinniss MJ, Nahas SA, ... ... Bejar R, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. PMID 26429975 DOI: 10.1182/Blood-2015-08-667063 |
0.478 |
|
| 2015 |
Bejar R. Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing? Current Hematologic Malignancy Reports. 10: 282-91. PMID 26126599 DOI: 10.1007/S11899-015-0270-5 |
0.482 |
|
| 2015 |
Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 126: 9-16. PMID 25931582 DOI: 10.1182/Blood-2015-03-631747 |
0.458 |
|
| 2015 |
Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, et al. Myelodysplastic syndromes, version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 261-72. PMID 25736003 DOI: 10.6004/Jnccn.2015.0038 |
0.352 |
|
| 2015 |
Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. The Journal of Clinical Investigation. 125: 1665-9. PMID 25705881 DOI: 10.1172/Jci78619 |
0.392 |
|
| 2015 |
Medina C, Drusbosky L, Chang M, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR. Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome Blood. 126: 96-96. DOI: 10.1182/Blood.V126.23.96.96 |
0.415 |
|
| 2015 |
Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Ogawa S, Fenaux P, Hellstrom-Lindberg E, Kern W, Boultwood J, et al. Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee Blood. 126: 907-907. DOI: 10.1182/Blood.V126.23.907.907 |
0.449 |
|
| 2015 |
Ademà V, Palomo L, Bartlomiej PP, Maria D, Hosono N, Mallo M, Xicoy B, Luño E, Patel BJ, Hirsch CM, Zamora L, LaFramboise T, Arenillas L, Perez-Ladaga A, Pedro C, ... ... Bejar R, et al. The Complete Mutatome and Clonal Architecture of Del(5q) Blood. 126: 608-608. DOI: 10.1182/Blood.V126.23.608.608 |
0.409 |
|
| 2015 |
Tanaka T, Reilly B, Diep D, Zhang K, Bejar R. Cytosine Methylation Patterns As Biomarkers in MDS Blood. 126: 5226-5226. DOI: 10.1182/Blood.V126.23.5226.5226 |
0.357 |
|
| 2015 |
Perez-Ladaga A, Xie H, Orkin SH, Sykes DB, Ebert BL, Bejar R. Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression Blood. 126: 4112-4112. DOI: 10.1182/Blood.V126.23.4112.4112 |
0.345 |
|
| 2015 |
Steensma D, Abedi M, Bejar R, Cogle C, Foucar K, Garcia-Manero G, George T, Grinblatt D, Komrokji R, Maciejewski J, Pollyea D, Roboz G, Savona M, Scott B, Sekeres M, et al. 249 CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY Leukemia Research. 39: S124. DOI: 10.1016/S0145-2126(15)30250-2 |
0.345 |
|
| 2014 |
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 26: 509-20. PMID 25242043 DOI: 10.1016/J.Ccr.2014.08.001 |
0.374 |
|
| 2014 |
Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 124: 2793-803. PMID 25237199 DOI: 10.1182/Blood-2014-04-522136 |
0.371 |
|
| 2014 |
Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 124: 2705-12. PMID 25224413 DOI: 10.1182/Blood-2014-06-582809 |
0.445 |
|
| 2014 |
Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2691-8. PMID 25092778 DOI: 10.1200/Jco.2013.52.3381 |
0.43 |
|
| 2014 |
Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica. 99: 956-64. PMID 24881041 DOI: 10.3324/Haematol.2013.085217 |
0.472 |
|
| 2014 |
Steensma DP, Abedi M, Attar EC, Bejar R, Cogle CR, Garcia-Manero G, Grinblatt DL, Ma X, Maciejewski JP, Pollyea DA, Roboz GJ, Savona M, Scott BL, Sekeres MA, Thompson MA, et al. Connect MDS and AML: The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) disease registry. Journal of Clinical Oncology. 32: TPS7126-TPS7126. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps7126 |
0.356 |
|
| 2014 |
Lord AM, Clement K, Schneider RK, Marie M, Chen MC, Levine RL, Mullally A, Galili N, Ali AM, Raza A, Bejar R, Meissner A, Ebert BL. Loss of TET2 Function in Myelodysplastic Syndrome Results in Intragenic Hypermethylation and Alterations in mRNA Splicing Blood. 124: 775-775. DOI: 10.1182/Blood.V124.21.775.775 |
0.365 |
|
| 2014 |
Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres MA, Walter MJ, Graubert TA, Cazzola M, Malcovati L, Campbell PJ, Ogawa S, Boultwood J, Bowen D, Tauro S, et al. TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee Blood. 124: 532-532. DOI: 10.1182/Blood.V124.21.532.532 |
0.472 |
|
| 2014 |
Adema V, Palomo L, Díez-Campelo M, Mallo M, Arenillas L, Luño E, Perez-Ladaga A, Yost S, Zamora L, Gomez-Marzo P, Xicoy B, Pedro C, Cañizo MC, Sanzo C, Lopez R, ... ... Bejar R, et al. Whole-Exome Sequencing in Myelodysplastic Syndromes with 5q Deletion Blood. 124: 4635-4635. DOI: 10.1182/Blood.V124.21.4635.4635 |
0.45 |
|
| 2014 |
Hall J, Hafidh JA, Balmert E, Dabbas B, Vaupel C, Hader CE, McGinniss M, Beruti S, Bejar R. Somatic Mutations Indicative of Clonal Hematopoiesis Are Present in a Large Fraction of Cytopenic Patients Who Lack Diagnostic Evidence of MDS Blood. 124: 3272-3272. DOI: 10.1182/Blood.V124.21.3272.3272 |
0.477 |
|
| 2013 |
Adema V, Bejar R. What lies beyond del(5q) in myelodysplastic syndrome? Haematologica. 98: 1819-21. PMID 24323981 DOI: 10.3324/Haematol.2013.094912 |
0.358 |
|
| 2013 |
Bejar R. Prognostic models in myelodysplastic syndromes. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013: 504-10. PMID 24319225 DOI: 10.1182/Asheducation-2013.1.504 |
0.443 |
|
| 2013 |
Bejar R, Abdel-Wahab O. The importance of subclonal genetic events in MDS. Blood. 122: 3550-1. PMID 24263953 DOI: 10.1182/Blood-2013-09-527655 |
0.342 |
|
| 2013 |
Murphy DM, Bejar R, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Mike Makrigiorgos G. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia. 27: 2077-81. PMID 23708912 DOI: 10.1038/Leu.2013.160 |
0.451 |
|
| 2013 |
Perez-Ladaga A, Caughey B, Xie H, Orkin SH, Sykes DB, Ebert BL, Bejar R. Functional Defects In Neutrophils Derived From Ezh2 Null Mice Blood. 122: 1556-1556. DOI: 10.1182/Blood.V122.21.1556.1556 |
0.342 |
|
| 2013 |
Adema V, Mallo M, Arenillas L, Díez-Campelo M, Luño E, Palomo L, Perez-Ladaga A, Yost S, Cheng C, Harismendy O, Zamora L, Xicoy B, Pedro C, Cañizo C, Sanzo C, ... ... Bejar R, et al. Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype Blood. 122: 1551-1551. DOI: 10.1182/Blood.V122.21.1551.1551 |
0.466 |
|
| 2013 |
Bejar R, Murphy D, Stevenson K, Neuberg D, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert B, Makrigiorgos G. P-103 Occult NRAS mutations with very low allele burden have independent prognostic significance in lower-risk myelodysplastic syndromes Leukemia Research. 37: S68-S69. DOI: 10.1016/S0145-2126(13)70151-6 |
0.409 |
|
| 2013 |
Bejar R, Stevenson K, Stojanov P, Zaneveld J, Bar-Natan M, Caughey B, Wang H, Garcia-Manero G, Kantarjian H, Cibulskis K, Getz G, Steensma D, Stone R, Chen R, Neuberg D, et al. O-024 Next-generation sequencing of 213 MDS patient samples identifies mutation profiles associated with response to hypomethylating agents and overall survival Leukemia Research. 37: S19-S20. DOI: 10.1016/S0145-2126(13)70046-8 |
0.369 |
|
| 2012 |
Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3376-82. PMID 22869879 DOI: 10.1200/Jco.2011.40.7379 |
0.4 |
|
| 2012 |
Bejar R, Stevenson KE, Stojanov P, Zaneveld JE, Bar-Natan M, Caughey B, Wang H, Garcia-Manero G, Kantarjian HM, Cutler C, Ritz J, Cibulskis K, Getz G, Steensma DP, Stone RM, et al. Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation Blood. 120: 311-311. DOI: 10.1182/Blood.V120.21.311.311 |
0.488 |
|
| 2011 |
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 364: 2496-506. PMID 21714648 DOI: 10.1056/Nejmoa1013343 |
0.448 |
|
| 2011 |
Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 504-15. PMID 21220588 DOI: 10.1200/Jco.2010.31.1175 |
0.455 |
|
| 2011 |
Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Galili N, Garcia-Manero G, Kantarjian HM, Raza A, Steensma DP, Levine RL, Neuberg D, Ebert BL. Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples Blood. 118: 969-969. DOI: 10.1182/Blood.V118.21.969.969 |
0.446 |
|
| 2011 |
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine R, Neuberg D, Ebert B. 288 Point mutations in myelodysplastic syndromes: Associations with clinical features and independent predictors of overall survival Leukemia Research. 35: S113. DOI: 10.1016/S0145-2126(11)70290-9 |
0.41 |
|
| 2010 |
Bejar R, Ebert BL. The genetic basis of myelodysplastic syndromes. Hematology/Oncology Clinics of North America. 24: 295-315. PMID 20359627 DOI: 10.1016/J.Hoc.2010.02.001 |
0.452 |
|
| 2010 |
Bejar R, Stevenson K, Abdel-Wahab O, Marie M, Lin K, McAuley JR, Cheung K, Galili N, Garcia-Manero G, Kantarjian H, Raza A, Levine R, Neuberg D, Ebert BL. Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival Blood. 116: 300-300. DOI: 10.1182/Blood.V116.21.300.300 |
0.469 |
|
| 2010 |
Heinrichs S, Conover L, Bueso-Ramos CE, Kilpivaara O, Levine R, Stevenson K, Neuberg D, Bejar R, Ebert BL, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 Is a Candidate Tumor Suppressor Gene In MDS Blood. 116: 1865-1865. DOI: 10.1182/Blood.V116.21.1865.1865 |
0.368 |
|
| 2002 |
Bejar R, Yasuda R, Krugers H, Hood K, Mayford M. Transgenic calmodulin-dependent protein kinase II activation: dose-dependent effects on synaptic plasticity, learning, and memory. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 5719-26. PMID 12097524 DOI: 10.1523/Jneurosci.22-13-05719.2002 |
0.636 |
|
| Show low-probability matches. |